PROFHILO® STRUCTURA (1 x 2 mL) | IBSA Derma (Italy)

Short Description

An advanced, regenerative subcutaneous bio-remodeling injectable formulated with 4.5% (45 mg/mL) ultrapure Hyaluronic Acid (Total 90 mg / 2 mL) utilizing patented NAHYCO® Thermal Hybrid Technology. Calibrated specifically for the superficial adipose tissue (SAT) plane, PROFHILO® Structura restores age-related subcutaneous fat atrophy, regenerates the adipose framework, and counteracts facial “sinking” and “sagging” phenotypes—delivering natural lipo-lifting, connective septa reinforcement, and lateral contour elevation with clinical durability lasting 6 to 9 months.

Detailed Description

PROFHILO® STRUCTURA is an advanced, sterile, non-pyrogenic physiological injectable developed in Italy by IBSA Farmaceutici / IBSA Derma. While classic Profhilo revolutionized dermal bioremodeling, Profhilo Structura addresses the deeper architectural cause of facial descent: superficial fat pad atrophy and the destabilization of subcutaneous connective tissue septa.

The formulation is synthesized using IBSA’s patented NAHYCO® Hybrid Technology:

• High-molecular-weight hyaluronic acid (H-HA: 1,100–1,400 kDa) and low-molecular-weight hyaluronic acid (L-HA: 80–100 kDa) are thermally bound together without chemical cross-linking agents (100% BDDE-free).

• This thermal stabilization forms Stable Cooperative Hybrid Complexes (HCC), yielding an unprecedented concentration of 45 mg/mL (90 mg per 2 mL pre-filled syringe)—one of the highest pure HA concentrations in clinical aesthetic medicine.

The “Lipo-Lifting” Cellular Mechanism

Rather than behaving like an inert volumizing gel or a superficial dermal hydrator, Profhilo Structura is engineered to interact directly with the cellular components of superficial adipose compartments:

1. Adipocyte Viability & Differentiation: Upregulates pre-adipocyte differentiation and counteracts chronological adipocyte senescence, helping fat cells retain their natural volume and metabolic vitality.

2. Retinacula Cutis Reinforcement: Stimulates collagen and elastin synthesis within the vertical and oblique fibrous septa (retinacula cutis) that anchor superficial fat pads to the overlying dermis and underlying superficial musculoaponeurotic system (SMAS).

3. Restoration of Structural Tightness: Provides cohesive mechanical lift without the rigid, hydrophilic fullness or pillow-face distortions associated with traditional cross-linked dermal fillers.

Treatment Areas & Indications

• Midface Lateral Deflation & Submalar Sinking:

  • Sinking cheekbones, flattened lateral midface contours, and hollowed pre-auricular zones

  • Age-related deflation of the lateral cheek superficial fat compartment

• Lower Face Ptosis & Gravitational Sagging:

  • Jowl formation and descent of facial fat toward the mandibular margin

  • Loss of jawline sharpness and soft-tissue laxity along the lower contour

• Facial Aging Phenotypes (Classification by IBSA):

  • Sinking Phenotype: Patients with thin skin, low subcutaneous adipose volume, and a hollowed/sunken facial appearance requiring subcutaneous replenishment.

  • Sagging Phenotype: Patients with heavier subcutaneous tissue that has descended vertically over time, requiring vector lift and structural redensification of the retaining septa.

Key Clinical Advantages

• High Total HA Load (90 mg / 2 mL): Delivers a 45 mg/mL concentration of ultrapure, uncross-linked HA, maximizing biological signaling while providing cohesive mechanical lift.

• True Adipose Tissue Bioremodeling: Specifically addresses superficial fat compartments (SAT), restoring deep facial scaffolding rather than merely hydrating the dermis.

• 100% BDDE-Free Safety Profile: Manufactured purely through thermal processing without synthetic chemicals, eliminating the risk of late-onset granulomas, delayed nodules, or foreign-body reactions.

• Natural Lipo-Lifting (Zero Over-Filling): Restores youthful anatomical proportions without creating the water-retentive “pillow face” effect common to cross-linked volumizers.

• Blunt-Cannula Delivery Comfort: Administered through a single entry point per side using a 25G or 22G blunt-tip microcannula, significantly reducing bruising, vascular risks, and clinical downtime.

• Rapid Clinical Protocol: Requires only two treatment sessions spaced 30 days apart, delivering cumulative tissue lifting that develops over 4 to 12 weeks.

Injection Protocol & Clinical Technique

Unlike classic Profhilo, which uses the 5-point BAP needle technique in the deep dermis, Profhilo Structura is strictly delivered into the Superficial Subcutaneous Adipose Tissue (SAT) using a blunt-tip microcannula:

• Target Anatomical Plane: Superficial Adipose Tissue (SAT)—placed above the SMAS and beneath the reticular dermis.

• Recommended Cannula: 25G x 38 mm or 25G x 50 mm blunt microcannula (with a 23G or 25G entry needle).

• Injection Technique:

  • A single insertion point is marked along the pre-auricular/zygomatic arch region.

  • The cannula is introduced into the superficial fat layer.

  • Product is deposited via retrograde linear fanning (0.5–1.0 mL per side) throughout the mid- and lower-cheek superficial fat compartments.

• Treatment Schedule: 2 sessions spaced 30 days apart. Maintenance protocol is recommended at 6 months.

Technical Specifications

Parameter	Specification
Product Classification	Subcutaneous Adipose Tissue Bioremodeling Injectable / CE Medical Device
Manufacturer / Origin	IBSA Farmaceutici Italia / IBSA Derma (Lugano, Switzerland / Italy)
Technology	Patented NAHYCO® Thermal Hybrid Technology (BDDE-Free)
HA Concentration	4.5% (45 mg/mL)
Total HA Content	90 mg per 2.0 mL syringe (45 mg H-HA + 45 mg L-HA)
Lidocaine Content	Lidocaine-free (local lidocaine wheal at cannula entry point recommended)
Packaging Presentation	1 x 2 mL pre-filled sterile glass syringe (or 2 x 1 mL packaging)
Target Injection Plane	Superficial Adipose Tissue (SAT) / Subcutaneous Fat Compartments
Recommended Injection Instrument	25G x 38 mm / 25G x 50 mm or 22G x 50 mm blunt-tip microcannula
Standard Clinical Protocol	2 sessions spaced 30 days (4 weeks) apart; 1 maintenance session at 6 months
Expected Clinical Duration	6 to 9 months
Storage Instructions	Store between 2°C and 25°C (36°F to 77°F); do not freeze; protect from light
Regulatory Category	CE-marked Class III Medical Device / Prescription Only (Rx)

Comparative Benchmark: Classic Profhilo vs. Profhilo Structura

Feature	PROFHILO® (Classic H+L)	PROFHILO® STRUCTURA
Primary Anatomical Target	Dermis (Interstitial Dermal Matrix)	Superficial Adipose Tissue (SAT / Fat Pads)
Total HA Load	64 mg / 2 mL (3.2% / 32 mg/mL)	90 mg / 2 mL (4.5% / 45 mg/mL)
Primary Clinical Goal	Dermal bioremodeling, hydration, glow, fine lines	Lipo-lifting, fat pad restoration, contour firmness
Clinical Presentation	“Crepey skin”, dullness, superficial laxity	“Sinking” or “sagging” midface, descending jowls
Delivery Tool	29G needle (BAP Technique — 5 bolus points per side)	25G / 22G blunt microcannula (Retrograde fanning)
Tissue Interaction	Keratinocyte & fibroblast collagen/elastin activation	Adipocyte viability + fibrous septa (retinacula cutis) remodeling
Analogy	“The fresh coat of paint & finishing polish”	“The structural timber frame holding the walls up”

Professional Advisory: PROFHILO® STRUCTURA is a specialized medical injectable intended strictly for certified aesthetic physicians, dermatologists, and plastic surgeons trained in cannula dissection within the superficial subcutaneous fat layer. Intradermal injection (which can cause persistent blebs due to the high 45 mg/mL viscosity) or deep periosteal/intravascular placement is strictly contraindicated.